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ABSTRACT 
Introduction: To evaluate the preoperative CEA and CA19-9 levels and their association with clinicopathologic features and 
mortality. Methods: This retrospective study was conducted on patients who underwent gastric surgery due to gastric 
adenocarcinoma from 2008 to 2015. Preoperative serum CEA and CA19-9 levels were compared according to the TNM 
classification and survival data were compared. Results: A total of 335 patients were included in the study with the mean age 
of 66.1±11.0 years. CEA and CA19-0 positivity were 29.1% and 28.1%, respectively. According to the CEA groups, T stages 
of the cases were statistically significant (p = 0.013). The rates of T stage 1 in group 1 (CEA positive) were significantly 
higher than the group 2 (CEA negative) (p=0.007). According to the CA19-9 positivity; rate of stage 2 was significantly higher 
in the group 1 (CA19-9 positive) (p=0.001); however, rates of stage 2 and 3 were significantly higher in the group 2 (CA19-9 
negative) (p=0.004 and p=0.007, respectively). Mortality information could be accessed for 309 cases and 108 deaths (36%) 
were observed. The mean survival time was 45.21±2.42 months. No significant difference was observed between the groups 
(p>0.05). Conclusion: Patients with higher levels of CEA and CA19-9 seem to have higher grades of gastric cancer. However, 
CEA and CA19-9 level does not seem to be in association in our study population. 
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umor markers (TMs) are the substances that are 
produced in response to the cancer and they are 
found in blood, urine or body tissues. Since the 
TMs may be measured quantitatively and have a 
causative association with the malignancies, they are 
usually used for the early detection or follow-up for 
various malignancies [1,2]. Although there is no precise 
TM for the gastric cancer, carcinoembryonic antigen 
(CEA) and carbohydrate antigen 19-9 (CA19-9) are widely 
used in the clinical practice. Until now, there are several 
studies considering the CEA and CA19-9 measurements in 
gastric cancer have been conducted in the literature [1-11]. 
However, sensitivity and specificity of these two TMs and 
their correlations with clinic or pathological features 
yielded conflicting results. Therefore, the objective of this  
 
study was to evaluate the preoperative CEA and CA19-9 
levels and their association with clinicopathologic features. 
MATERIALS & METHODS 
This study was conducted retrospectively and patients who 
underwent gastric surgery, in the general surgery 
department of our hospital with the pathologic diagnosis of 
gastric adenocarcinoma between the years 2008 and 2015, 
were included. Patients, who underwent surgery for the 
tumor recurrence, had an unresectable tumor, and were 
diagnosed with other pathologic diagnosis, were excluded 
from the study. Demographical features such as age and 
gender, laboratory parameters, pathologic reports were 
collected from the hospital records retrospectively. 
Correlation between the preoperative CA19-9 and CEA 
T 
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levels and clinicopathologic factors (age, gender, tumor 
level, lymph node metastasis occurrence, serousal 
invasion) were explored. Since the study was retrospective, 
ethics committee approval was not received. 
Preoperative serum CEA and CA19-9 levels were 
measured with the electrochemiluminescence 
immunoanalyzer technique, as suggested in the literature 
(1). Blood specimens were obtained pre-operatively within 
the one-week. According to the instructions of the 
manufacturer, the cut-off levels of CEA and CA19-9 were 
accepted as 5 ng/mL and 37 U/mL, respectively. The 
patients were classified and graded according to the 7th 
edition of American Joint Committee on Cancer tumor, 
node, and metastasis (TNM) classification and staging 
system for gastric cancer.  
Number Cruncher Statistical System (NCSS) program 
version 2007 (Kaysville, Utah, USA) was used for 
statistical analysis. The Pearson Chi-Square test and the 
Yates 'Continuity Correction test (Chi-square test with 
Yates' correction) were used to compare qualitative data as 
well as descriptive statistical methods (mean, standard 
deviation, median, minimum, maximum). Kaplan Meier 
Survival analysis and Log Rank test were used to assess 
survival. Significance was assessed at p <0.01 and p <0.05 
levels. 
RESULTS 
A total of 335 patients were included in the study; out of 
them, 226 were male and 109 were female and their mean 
age was 66.1±11.0 years. Clinical features and laboratory 
parameters of the patients are summarized in table 1. The 
patients were allocated into two groups according to the 
CEA positivity. Comparison of the patients according to 
the CEA positivity is summarized in table 2.  
According to the CEA groups, T stages of the cases 
were statistically significant (p = 0.013). According to 
binary comparisons; the rates of T stage 1 in group 1 were 
significantly higher than the group 2 (p=0.007) whereas 
rates of T stage 4 were significantly higher in the group 2 
(p=0.029). While rate of stage 2 was significantly higher in 
the group 1 (p=0.006), rate of stage 3 was significantly 
higher in the group 2 (p=0.001). CEA and CA19-0 
positivity were 29.1% and 28.1%, respectively. 
Table-1: Clinical features and laboratory parameters 
of patients 
 
 
Figure 1: Survival of the gastric cancer patients          
The patients were allocated into two groups according 
to the CA19-9 positivity. Comparison of the patients 
according to the CA19-9 positivity is summarized in table 
3. Rate of stage 2 was significantly higher in the group 1 
(p=0.001); however, rates of stage 2 and 3 were 
Parameters Min – Max Mean ± SD 
Follow-up Period (M) 1 – 96  20.24±20.33 
Positive Lymph Node 1 – 52  8.72±8.12 
  n % 
CEA 
Negative 238 71.0 
Positive 97 29.0 
CA19-9 
Negative 239 71.3 
Positive 96 28.6 
T Stage 
Stage 1 20 6.0 
Stage 2 21 6.3 
Stage 3 111 33.1 
Stage4 183 54.6 
TNM 
Stage 
Stage1 25 7.5 
Stage2 68 20.3 
Stage 3 232 69.3 
Stage4 10 3.0 
Histologic 
Grade 
Grade 1 20 6.0 
Grade 2 126 37.6 
Grade 3 189 56.4 
Mortality 
No 201 65.0 
Yes 108 35.0 
Surgery 
Gastrectomy, Total 203 60.6 
Gastrectomy, 
Subtotal 
132 39.4 
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significantly higher in the group 2 (p=0.004 and p=0.007, 
respectively). 
Table-2: Comparison of the patients according to the CEA 
levels 
 
 
CEA 
 
P value 
Group 1, <5 
(n=238) 
Group 2, 
≥5 (n=97) 
T Stage Stage 1 20 (8.4) 0 (0) a0.013 
Stage 2 15 (6.3) 6 (6.2) 
Stage 3 82 (34.5) 29 (29.9) 
Stage 4 121 (50.8) 62 (63.9) 
Stage Stage 1 22 (9.2) 3 (3.1) a0.003 
Stage 2 58 (24.4) 10 (10.3) 
Stage 3 151 (63.4) 81 (83.5) 
Stage 4 7 (2.9) 3 (3.1) 
Grade Grade1 16 (6.7) 4 (4.1) a0.565 
Grade2 91 (38.2) 35 (36.1) 
Grade3 131 (55) 58 (59.8) 
Positive 
Lymph 
Node 
No 56 (23.5) 6 (6.2) b0.001 
Yes  182 (76.5) 91 (93.8) 
a
Pearson Chi-Square Test  
b
Yates’ Continuity Correction 
Test. P value <0.05 was considered as significant. 
The mortality information could be accessed for 309 
cases and 108 deaths (36%) were observed with the mean 
survival time of 45.21±2.42 months. The latest death was 
seen at the 96th month. Survival analyses according to 
CEA and CA19-9 measurements are shown in table 4 and 
5. No significant difference was observed between the 
groups (all p>0.05). The survival rates, according to the 
groups, were evaluated by Log Rank test and there was no 
statistically significant difference between 8-year survival 
rates (p: 0.649) (Figure 2 and 3).  
Table-3: Comparison of the patients according to the 
CA19-9 levels 
 
 
CA19-9 
P value Group 1 
<37 (n=239) 
Group 2 
≥37 (n=96) 
T Stage Stage 1 18 (7.5) 2 (2.1) 
a0.093 
Stage 2 18 (7.5) 3 (3.1)  
Stage 3 78 (32.6) 33 (34.4)  
Stage 4 125 (52.3) 58 (60.4)  
Stage Stage 1 22 (9.2) 3 (3.1) 
a
0.001 
Stage 2 60 (25.1) 8 (8.3)  
Stage 3 154 (64.4) 78 (81.3)  
Stage 4 3 (1.3) 7 (7.3)  
Grade Grade1 17 (7.1) 3 (3.1) 
a0.324 
Grade2 91 (38.1) 35 (36.5)  
Grade3 131 (54.8) 58 (60.4)  
Positive 
Lymph  
Node 
No 56 (23.4) 6 (6.3) 
b
0.001 
Yes 183 (76.6) 90 (93.8) 
 
a
Pearson Chi-Square Test  
bYates’ Continuity Correction 
Test. P value <0.05 was considered as significant. 
 
Figure 2: Survival of the gastric cancer patients according 
to the CEA levels 
Table 4: Survey Analysis According to the CEA and CA19-9 Levels 
 N Expired Living Survival Rate Mean Survival Time 95% CI 
CEA<5 219 92 127 58.0 45.13±2.65 39.93-50.33 
CEA≥5 90 16 74 82.2 38.44±3.51 31.57-4532 
CA199<37 222 87 135 60.8 45.76±2.69 40.49-51.04 
CA199≥37 87 21 66 75.9 42.00±4.97 32.26-51.73 
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Figure 3: Survival of the gastric cancer patients according 
to the CA19-9 levels 
DISCUSSION  
In this retrospective study, we intended to explore the 
role of preoperative CEA and CA19-9 levels and their 
association with clinicopathologic features. According to 
our results, we have two main findings. First, the patients 
with higher levels of CEA and CA19-9 levels had higher 
grades of gastric cancer. Second, CEA and CA19-9 level 
were not associated with the mean survival. The clinical 
significance of CEA and CA19-9 in gastric cancer has 
been studied previously also.  
Shimada et al [12] evaluated the clinical significance of 
serum tumor markers (CEA, CA19-9, and CA72-4) in 
gastric cancer patients in their review. They have 
conducted a systematic literature search and included a 
total of 187 publications. According to their results, 
positivity rates of the CEA and CA19-9 were 21.1% and 
27.8%, respectively. On the contrary to this study, some 
studies have also reported different rates of positivity of 
CEA and CA19-9 [1,8]. Moreover, they highlighted that 
TMs were associated with the stage of the tumor and 
survival. Since the positivity rates were small, the use of 
these TMs for the screening tool was not suggested. By 
contrast, monitoring of the TMs is convenient –the TMs 
become positive approximately two months before the 
radiologic occurrence and for the post-operative follow-up.  
According to our results, the positivity rates of CEA 
and CA19-9 were 29.1% and 28.1%, respectively. While 
we found a significant relation with the stages and level of 
the TMs, we did not find a relation with the survival and 
level of TMs. This fact could be related to the sample size, 
study populations, and particularly the normal distribution 
of the cases included in the study. For instance, the 
incidence of the gastric cancer in Japan is significantly 
higher than that of United States and western countries. 
Differences in Helicobacter pylori infection, food storage, 
dietary habits, environmental factors, genetic 
predisposition, lifestyles, and smoking may be the 
underlying factors. By the way, detection of the tumor in 
an early stage might affect the survival [13]. Yu et al. [8] 
suggested that the combination of the TMs would be more 
sensitive. In our study, we did not study relation of the 
combination of the CEA and CA19-9, which is a limitation 
of this study.   
As for the association with the stages of gastric cancer 
and CEA or CA19-9 in the literature, Sisik et al. [14] 
included 49 patients with gastric cancer in their study and 
concluded that CEA and CA19-9 positivity could be 
indicative for an advanced stage. Komada et al. [15] 
compared the CA72-4 levels with CA19-9 and CEA in 100 
patients whereby, CA 72-4 gave the highest positivity rate 
for the advanced cancers. Additionally, CEA and CA19-9 
levels were higher in the advanced stages of cancer. 
Similarly, in our study CEA and CA19-9 levels were 
significantly higher in the higher stages of the cancer. 
However, differently from the previous studies, we have 
included only the patients with resectable tumor. Patients 
with distant organ metastasis and unresectable tumor were 
excluded. This condition might have affected our results. 
In addition, lack of CA72-4 evaluation is a limitation of 
our study. Since we did not measure the levels of CA72-4, 
we could not compare the data with respect to the CA72-4 
levels. Lymph node positivity and levels of CEA and 
CA19-9 were found to be associated in the previous 
studies [8]. Similarly, we found higher levels of TMs in 
patients with positive lymph nodes. 
CONCLUSION 
Our results showed that patients with higher levels of CEA 
and CA19-9 had higher grades of gastric cancer. However, 
CEA and CA19-9 levels were not associated with the 
survival in our study population. Further studies 
considering association of the TMs, maybe the 
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combination of the TMs, with the survey analysis in cohort 
designs are awaited. 
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